🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

We’re pleased to announce that Federation Bio has come out of stealth mode with a $50 million Series A financing, two novel #microbial therapeutic platforms and an exceptional leadership team. Watch to see what we do next! Read the press release here: prn.to/34wujFF

We’re pioneering new approaches for treating intractable diseases by combining an unprecedented number of #microbial strains into highly diverse consortia, in some instances optimized with genetically engineered bacteria to enhance the immune system. Federation.bio

Emerging scientific understanding of the human #microbiome has demonstrated the profound role that microbes play in human physiology and rapidly elevated their therapeutic potential. Learn more about our novel approach at Federation.bio

An emerging scientific understanding of the human #microbiome is transforming our relationship with microbes – elevating them from menace to medicine as our understanding of their profound role in human physiology has come into focus. Learn more at Federation.bio

Thanks to Venrock for featuring Federation.Bio CEO Emily Drabant Conley on the #RunningThroughWalls podcast! Tune in to hear Emily Drabant Conley discuss leadership lessons from her time at 23andMe and how Federation Bio is disrupting the #microbiome space: vnrk.co/3hM7hkB

Today, we administered the first dose of our investigational bacterial cell therapy, FB-001. This Phase 1 #clinicaltrial will evaluate the safety, efficacy and engraftment of FB-001 in the treatment of enteric #hyperoxaluria, a serious metabolic disorder. prn.to/3FBXqeF

Today, we announced a collaboration with MD Anderson Cancer Center to develop a novel #microbiome treatment for individuals with immunotherapy-resistant #cancer. Read today’s press release at prn.to/3kUl9id.

#ICYMI Yesterday, we announced a collaboration with MD Anderson Cancer Center that will join MD Anderson’s expertise with our proprietary ACT bacterial #celltherapy platform to develop a novel treatment for individuals with #immunotherapy-resistant #cancer.